Literature DB >> 10404829

Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

M Wøjdemann1, A Wettergren, B Hartmann, L Hilsted, J J Holst.   

Abstract

Glucagon-like peptide (GLP)-2 is formed from proglucagon in the intestinal L cells and is secreted postprandially in parallel with the insulinotropic hormone GLP-1, the latter of which, in addition, acts to inhibit gastric secretion and motility by inhibiting central parasympathetic outflow. We now studied the effect of GLP-2 on gastric secretion stimulated by sham feeding to test the hypothesis that also GLP-2 acts as an enterogastrone. Eight healthy volunteers were studied twice on separate days. They were sham fed with and without GLP-2 infused iv at a rate of 0.8 pmol/kg x min. Gastric contents were aspirated continuously by a nasogastric tube for determination of acid secretion, volume, and osmolarity. Sham feeding increased gastric acid secretion nearly 5-fold. Infusion of GLP-2 reduced incremental acid secretion by 65+/-6%, compared with saline infusion (delta8.75+/-0.37 vs. delta3.04+/-0.47 mmol x 60 min; P<0.01). Plasma concentrations of GLP-2 rose from a basal mean of 3.3+/-0.9 to a mean of 115+/-8 pmol/L (range, 57-149 pmol/L) during infusion of GLP-2 and remained at basal level during saline infusion. Plasma concentrations of GLP-1, gastrin, cholecystokinin, and secretin remained low and unchanged on both study days. We conclude that GLP-2 is a powerful inhibitor of gastric acid secretion in man. Further investigations will show to what extent GLP-2 contributes to the inhibitory effects on gastric secretion exerted by hormones from the distal small intestine, under physiological circumstances.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404829     DOI: 10.1210/jcem.84.7.5840

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  Gut adaptation and the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 2.  Enhancing bowel adaptation in short bowel syndrome.

Authors:  Palle Bekker Jeppesen; Per Brobech Mortensen
Journal:  Curr Gastroenterol Rep       Date:  2002-08

3.  Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.

Authors:  Bharati Kochar; Millie D Long; Edward Shelton; Lorraine Young; Francis A Farraye; Vijay Yajnik; Hans Herfarth
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

Review 4.  Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.

Authors:  G-R Martin; P-L Beck; D-L Sigalet
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

5.  Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.

Authors:  P B Jeppesen; E L Sanguinetti; A Buchman; L Howard; J S Scolapio; T R Ziegler; J Gregory; K A Tappenden; J Holst; P B Mortensen
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 6.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

7.  Increased GLP2R expression in gastric chief cells of patients with severe obesity regardless of diabetes status.

Authors:  F Li; L Lu; Y Peng; Y Zhang; J Gao; D Zhou; D Zhou; H Sheng; S Qu
Journal:  Int J Obes (Lond)       Date:  2017-03-24       Impact factor: 5.095

8.  Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

Authors:  J Thulesen; B Hartmann; K J Hare; H Kissow; C Ørskov; J J Holst; S S Poulsen
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

Authors:  Sara Baldassano; Sumei Liu; Mei-Hu Qu; Flavia Mulè; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

10.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.